ROCKVILLE, Md.--(BUSINESS WIRE)--Dec. 15, 2005--20/20 GeneSystems, Inc. (“20/20") today announced that it has acquired exclusive rights from the University of Kentucky to a new blood test that has shown exceptional accuracy for the early detection and screening of non-small cell lung cancer (NSCLC). Working with the team from Kentucky and other leading medical and scientific groups the company intends to develop a diagnostic that would help identify lung cancer in smokers, former smokers and other at-risk individuals at its earliest, most effectively treatable stages.
